Published in Gene Therapy Weekly, August 1st, 2002
The patent relates to treatment methods employing the mda-7 tumor suppressor gene. The mda-7 gene is the subject of Introgen's gene therapeutic INGN 241 currently being tested in a phase 1 clinical trial for the treatment of solid tumors in cancer patients. Clinical data from this trial will be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.